CoChat

FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

Elkins, Kristi, Zheng, Bing, Go, MaryAnn, Slaga, Dionysos, Du, Changchun, Scales, Suzie J., Yu, Shang-Fan, McBride, Jacqueline, de Tute, Ruth, Rawstron, Andy, Jack, Andrew S., Ebens, Allen, Polson, Andrew G. · 2012 · Molecular Cancer Therapeutics
Cited by 97

The DOI matches its Crossref record.

Abstract

Fc receptor-like 5 (FcRL5/FcRH5/IRTA2/CD307) is a surface protein expressed selectively on B cells and plasma cells. We found that FcRL5 was expressed at elevated levels on the surface of plasma cells from the bone marrow of patients diagnosed with multiple myeloma. This prevalence in multiple myeloma and narrow pattern of normal expression indicate that FcRL5 could be a target for antibody-based therapies for multiple myeloma, particularly antibody–drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via specialized chemical linkers, where limited expression on normal tissues is a key component to their safety. We found that FcRL5 is internalized upon antibody binding, indicating that ADCs to FcRL5 could be effective. Indeed, we found that FcRL5 ADCs were efficacious in vitro and in vivo but the unconjugated antibody was not. The two most effective consisted of our anti-FcRL5 antibody conjugated through cysteines to monomethylauristatin E (MMAE) by a maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-vcPAB) linker (anti-FcRL5-MC-vcPAB-MMAE) or conjugated via lysines to the maytansinoid DM4 through a disulfide linker (anti-FcRL5-SPDB-DM4). These two ADCs were highly effective in vivo in combination with bortezomib or lenalidomide, drugs in use for the treatment of multiple myeloma. These data show that the FcRL5 ADCs described herein show promise as an effective treatment for multiple myeloma. Mol Cancer Ther; 11(10); 2222–32. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-12-0087

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 97

Metadata

Authors
Elkins, K., Zheng, B., Go, M., Slaga, D., Du, C., Scales, S. J., Yu, S.-F., McBride, J., de Tute, R., Rawstron, A., Jack, A. S., Ebens, A., & Polson, A. G.
Venue
Molecular Cancer Therapeutics
Published
2012-10-01
Volume
11
Issue
10
Pages
2222-2232
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2146480092
Cited by
97
References
0
FWCI
1.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0087
The paper
Elkins, K., Zheng, B., Go, M., Slaga, D., Du, C., Scales, S. J., Yu, S.-F., McBride, J., de Tute, R., Rawstron, A., Jack, A. S., Ebens, A., & Polson, A. G. (2012). FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.